Latest News and Press Releases

Clinical responses point to the NOX66 DARRT treatment regimen as a potentially major new treatment option for men with late-stage prostate cancerPositive results trigger planning for proposed pivotal...

Noxopharm has appointed Mr Alexander Hunter as Chief Commercial OfficerMr Hunter is an experienced corporate finance and business executive with a background in high growth listed company operations...

Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancerBased on recent international...

Comparative data shows Veyonda® significantly boosts the effectiveness of a promising new form of radiation therapy (177LuPSMA) in advanced prostate cancer177LuPSMA therapy is the subject of a recent...

Research relating to Veyonda® in the treatment of advanced prostate cancer is to be included in a key Australian oncology meetingBoth Noxopharm and independent investigators have abstracts...

SYDNEY, Australia, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today announced the interim three month results from the second part of the DARRT-1 study on...

Veyonda® is being developed as a transformative anti-cancer treatment (DARRT) in combination with radiotherapy to produce off-target responses known as an abscopal effectPre-clinical studies now...

Positive results from two prostate cancer trialsPhase 2 trial design gaining momentumInvestigational New Drug Application to be submitted to FDA in Q3 2019Pipeline developing based on drug discovery...